Boehringer Ingelheim's worldwide Research & Development Sites
Research & development at Boehringer Ingelheim is conducted at four major research & development sites and three support centres worldwide. We employ more than 7,000 scientists, technicians and support staff, clinical monitors, statisticians and data managers. Clinical research is conducted in 87 countries all over the world.
The bridge between industry and academia is strengthened by the Research Institute of Molecular Pathology (IMP) in Vienna (Austria)
R&D Sites
-
Biberach and Ingelheim, Germany
Research & Development Areas:
- Respiratory diseases
- Cardiometabolic diseases
-
Neurological diseases
- Non-clinical drug development
Country Website:
-
Ridgefield, USA
Country Website
-
Vienna, Austria
Country Website:
-
Laval, Canada
Country Website:
Support Centres
-
Kobe, Japan
Support centre for molecular biology and non-clinical drug development:
- Support for international drug discovery activities
- Early drug formulation
- Specific pharmacokinetic investigations
Country Website
-
Buenos Aires, Argentina
Support centre for non-clinical development:
- Support on drug formulation and manufacturing of medication for clinical trials
Country Website:
- Support on drug formulation and manufacturing of medication for clinical trials
-
Milan, Italy
Support centre for chemical synthesis:
- Support for synthesis in exploratory and lead optimisation projects
Country Website:
